Mavacamten in Nonobstructive Hypertrophic Cardiomyopathy
Abstract
To the Editor: In the article by Desai et al. (Sept. 11 issue) 1 on mavacamten in patients with nonobstructive hypertrophic cardiomyopathy (HCM), the results for both coprimary end points — the change from baseline to week 48 in peak oxygen uptake and in the Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS; scores range from 0 to 100, with higher scores indicating better health status) — narrowly missed statistical significance with P values of 0.07 and 0.06, respectively. Others have cautioned that exploratory mechanistic findings should not be used to reinterpret a negative trial as positive. 2 The trial may have . . .
Fields of Study & Subjects
Cardiomyopathy and Myosin Studies
Cardiovascular Effects of Exercise
Blood Pressure and Hypertension Studies
Publication details
- Journal / source
- New England Journal of Medicine
- Volume
- 394
- Issue
- 6
- Pages
- 616–618
- Publication date
- 4 February 2026
- Language
- EN